The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab

Human Antibodies

Volumn 20, Issue 1-2, 2011, Pages 37-40

  Tran, L ^a   Baars, J W ^b   De Boer, J P ^b   Hoefnagel, C A ^b   Beijnen, J H ^a,c   Huitema, A D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; IODINE 131; RITUXIMAB; RITUXIMAB I 131; UNCLASSIFIED DRUG; 131I RITUXIMAB; 131I-RITUXIMAB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

AGED; ANEMIA; ARTICLE; BIOLOGICAL ACTIVITY; CASE REPORT; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; LARGE CELL LYMPHOMA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIODINATION; SKIN BIOPSY; THROMBOCYTOPENIA; B LYMPHOCYTE; BIOSYNTHESIS; DRUG ADMINISTRATION; HALF LIFE TIME; IMMUNOLOGY; ISOTOPE LABELING; METABOLISM; METHODOLOGY; PATHOLOGY; RADIOIMMUNOTHERAPY; RECURRENT DISEASE; REMISSION; TISSUE DISTRIBUTION; TREATMENT OUTCOME; WHOLE BODY IMAGING;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; LYMPHOMA, NON-HODGKIN; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RECURRENCE; REMISSION INDUCTION; TISSUE DISTRIBUTION; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 79955876732     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-2011-0240     Document Type: Article

References (16)

1. D.G. Maloney, A.J. Grillo-Lopez, C.A. White, D. Bodkin, R.J. Schilder, J.A. Neidhart, N. Janakiraman, K.A. Foon, T.M. Liles, B.K. Dallaire, K. Wey, I. Royston, T. Davis and R. Levy, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood 90 (1997), 2188-2195. (Pubitemid 27392702)
2. R.I. Fisher, M.S. Kaminski, R.L. Wahl, S.J. Knox, A.D. Ze-lenetz, J.M. Vose, J.P. Leonard, S. Kroll, S.J. Goldsmith and M. Coleman, Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas, J Clin Oncol 23 (2005), 7565-7573. (Pubitemid 46291820)
3. T.E. Witzig, Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma, Semin Oncol 30 (2003), 11-16. (Pubitemid 38049932)
4. M.S. Kaminski, K.R. Zasadny, I.R. Francis, A.W. Milik, C.W. Ross, S.D. Moon, S.M. Crawford, J.M. Burgess, N.A. Petry and G.M. Butchko, Radioimmunotherapy of B-cell lymphoma with anti-B1 (anti-CD20) antibody, N Engl J Med 329 (1993), 459-465. (Pubitemid 23222331)
5. O.W. Press, J.F. Eary, F.R. Appelbaum, P.J. Martin, W.B. Nelp, S. Glenn, D.R. Fisher, B. Porter, D.C. Matthews and T. Gooley, Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas, Lancet 346 (1995), 336-340.
6. O.W. Press, J.F. Eary, F.R. Appelbaum, P.J. Martin, W.B. Nelp, S. Glenn, D.R. Fisher, B. Porter, D.C. Matthews and T. Gooley, Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas, Lancet 346 (1995), 336-340.
7. P.J. Fraker and J.C. Speck, Jr., Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a, 6a-diphrenylglycoluril, Biochem Biophys Res Commun 80 (1978), 849-857. (Pubitemid 8305904)
8. A.E. Bolton and W.M. Hunter, A new method for labelling protein hormones with radioiodine for use in the radioim-munoassay, J Endocrinol 55 (1972).
9. T.K. Nikula, M. Bocchia, M.J. Curcio, G. Sgouros, Y. Ma, R.D. Finn and D.A. Scheinberg, Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreac-tivity, Mol Immunol 32 (1995), 865-872.
10. S. Matzku, H. Kirchgessner and M. Nissen, Iodination of monoclonal IgG antibodies at a sub-stoichiometric level: im-munoreactivity changes related to the site of iodine incorporation, Int J Rad Appl Instrum B 14 (1987), 451-457. (Pubitemid 17135088)
11. T.Lindmo, E.Boven, F. Cuttitta, J. Fedorko and P.A. Bunn, Jr., Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess, J Immunol Methods 72 (1984), 77-89. (Pubitemid 14091996)
12. L. Tran, J.W. Baars, H.J. Maessen, C.A. Hoefnagel, J.H. Beij-nen and A.D. Huitema, A simple and safe method for 131I ra-diolabeling of rituximab for myeloablative high-dose radioim-munotherapy, Cancer Biother Radiopharm 24 (2009), 103-110.
13. Z.K. Indik, J.G. Park, S. Hunter and A.D. Schreiber, Structure/function relationships of Fc gamma receptors in phagocytosis, Semin Immunol 7 (1995), 45-54.
14. J.K. Kim, M. Firan, C.G. Radu, C.H. Kim, V. Ghetie and E.S. Ward, Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn, Eur J Immunol 29 (1999), 2819-2825. (Pubitemid 30099006)
15. S. Krapp, Y. Mimura, R. Jefferis, R. Huber and P.Sondermann, Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity, J Mol Biol 325 (2003), 979-989. (Pubitemid 36263407)
16. K. Tobinai, Y. Kobayashi, M. Narabayashi, M. Ogura, Y. Kagami, Y. Morishima, T. Ohtsu, T. Igarashi, Y. Sasaki, T. Ki-noshita and T. Murate, Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group, Ann Oncol 9 (1998), 527-534. (Pubitemid 28270641)